Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PBS Vax HIV Vaccine
- Development stage
- Unknown
- Lead developer
- Aurobindo Pharma
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
The PBS Vax™ HIV Vaccine is a clinical-stage, prime-boost vaccine candidate developed by Auro Vaccines (formerly Profectus BioSciences) for the prevention and treatment of HIV infection. The regimen employs a dual-modality approach: a GeneVax™ DNA prime, which is a multi-antigen HIV DNA vaccine encoding env, gag, pol, nef, tat, and vif, co-formulated with IL-12 as a molecular adjuvant and delivered via electroporation; followed by a VesiculoVax™ viral-vector boost, which is a recombinant vesicular stomatitis virus (rVSV)-based vector encoding HIV gag. The vaccine is designed to induce robust CD4+ and CD8+ T cell-mediated immune responses against multiple HIV antigens. A Phase 1 clinical trial (HVTN 087) demonstrated that the GeneVax™-primed T cell responses were synergistically boosted by the VesiculoVax™ vector.
- Brand names
- PBS Vax
- Other names
- GeneVax + VesiculoVax HIV vaccineProfectus HIV vaccine
02
Targets
IL-12R (Interleukin-12 receptor)gp41 (Human immunodeficiency virus type 1 glycoprotein 41)Gag (HIV-1 Gag polyprotein)Nef (HIV-1 Nef)Human immunodeficiency virus type 1 reverse transcriptaseTat (HIV-1 Tat)Vif (HIV-1 Vif)
Beyond the preview
Go deeper on PBS Vax HIV Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PBS Vax HIV Vaccine.